The ALPL Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the human ALPL gene. This product comprises a heterogeneous pool of HAP1 cells carrying various gene disruptions introduced by non-homologous end joining, creating a genetically diverse loss-of-function model. Unlike monoclonal lines, the polyclonal format preserves population-level biological variation and minimizes clonal selection bias, making it ideal for studies requiring robust and reproducible phenotypes.
HAP1 is a near-haploid cell line established from the KBM-7 chronic myeloid leukemia line. Its haploid karyotype ensures that a single CRISPR-induced mutation yields a null phenotype, simplifying genetic analysis. These adherent cells are widely employed in high-throughput screens and mechanistic research. For ALPL, this background guarantees complete loss of TNAP activity, providing a clean model for studying phosphate homeostasis and mineralization defects.
ALPL encodes tissue-nonspecific alkaline phosphatase (TNAP), which hydrolyzes pyrophosphate into inorganic phosphate for hydroxyapatite formation. TNAP also dephosphorylates osteopontin and is transcriptionally activated by RUNX2, downstream of Wnt/??-catenin signaling, and modulated by the vitamin D receptor. It functions within matrix vesicles, requiring zinc and calcium cofactors and interacting with collagen type I. Disruption of ALPL leads to pyrophosphate accumulation and impaired mineralization, recapitulating hypophosphatasia defects. This model thus enables dissection of phosphate homeostasis and the molecular events governing skeletal mineralization.
In the HAP1 background, the ALPL knockout model allows study of TNAP’s intrinsic enzymatic functions independent of osteoblastic differentiation. When co-cultured with osteogenic cells, these knockout cells can reveal the contribution of TNAP-derived inorganic phosphate to mineralization. The polyclonal nature mirrors the heterogeneous mutations in hypophosphatasia, making it useful for genotype?Cphenotype correlation and therapeutic screening.
These cells are suitable for alkaline phosphatase activity assays, co-culture mineralization models assessed by Alizarin Red staining, and RT-qPCR profiling of osteoblast markers. Western blotting and immunofluorescence verify ALPL loss and TNAP localization. They enable high-throughput drug screening to identify modulators of phosphate generation and functional genomics to uncover genetic interactors. For further information, contact Ascent Research.
